Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Deshaw

Optometrist Garland, TX Doctor of Optometry

NPI 1407160815 CMS profile 1228738

2636 W Walnut St Ste 200, Garland, TX 75042

Open in the dashboard

General payments

$4,933

66 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Deshaw of Garland, TX is reported in the CMS Open Payments database as having received $4,933 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $996 11
2024 General $283 5
2023 General $733 10
2022 General $942 16
2021 General $173 3
2020 General $247 6
2019 General $1,559 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Deshaw
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Jonathan Deshaw were reported at $996. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Jonathan Deshaw Optometrist median Middle half National median
2019 $1,559 $159 $67–$371 $163
2020 $247 $72 $29–$165 $114
2021 $173 $125 $46–$292 $132
2022 $942 $162 $66–$374 $149
2023 $733 $177 $72–$406 $160
2024 $283 $188 $77–$427 $164
2025 $996 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,347 15 payments
  2. Bausch & Lomb Americas Inc. $1,047 16 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $349 9 payments
  4. LKC Technologies, Inc. $249 3 payments
  5. CooperVision Inc. $249 3 payments
  6. TissueTech, Inc. $236 3 payments
  7. Sun Pharmaceutical Industries Inc. $219 2 payments
  8. ABB Con-Cise Optical Group LLC $167 1 payment
  9. Novartis Pharmaceuticals Corporation $130 2 payments
  10. Aerie Pharmaceuticals, Inc. $127 1 payment
  11. Other $813 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,310 62 payments
  2. Travel and Lodging $511 2 payments
  3. Entertainment $93 1 payment
  4. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. DAILIES $915 9 payments
  2. AIR OPTIX $839 6 payments
  3. INFUSE $823 13 payments
  4. Cequa $219 2 payments
  5. ULTRA $176 6 payments
  6. CONTACT LENS $167 1 payment
  7. Rhopressa $127 1 payment
  8. Rocklatan $127 1 payment
  9. ULTRA MULTIFOCAL TORIC $125 1 payment
  10. MIEBO $125 1 payment
  11. Other $2,945 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

140

Median for Optometry: 120

Drug cost

$1,653

Median for Optometry: $8,864

Branded share of claims

32.1%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 16 $473
Latanoprost Generic 57 $380
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 31 $365
Timolol Maleate Generic 22 $241
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 14 $194

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$2,248

Medicare's payments for the services billed

Medicare patients

17

Average age 65

Services billed

36

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record